HARNESSING THE EVOLUTIONARY POWER OF

T CELLS TO FIGHT SOLID TUMORS

HARNESSING THE EVOLUTIONARY POWER OF T CELLS TO FIGHT SOLID TUMORS

WHO WE ARE

Eureka Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing transformative technology platforms that can access cancer-specific targets and harness the evolutionary power of T cells for the treatment of solid tumors and other malignancies.

MORE ABOUT EUREKA

TWO PROPRIETARY PLATFORMS

E-ALPHA®

Leveraging high-throughput
screening to develop cancer-
specific antibodies.

EXPLORE THE PLATFORMS

Our pipeline highlights the unlimited potential of the ARTEMIS and E-ALPHA platforms to transform the treatment of cancer.

CANCER INDICATION

  • DISCOVERY
  • PRECLINICAL
  • PHASE I/II
  • PHASE III
TRAVERSE THE PIPELINE

The EUREKA THERAPEUTICS® approach to fighting solid tumors is to develop multiple potential treatment options for patients by cultivating a deeper understanding of each type of cancer and leveraging our cutting-edge technology platforms.

CURRENT CLINICAL TRIALS

NEWS UPDATE

Press releases
02 April 2024
Eureka Therapeutics Announces UCSF Benioff Children’s Hospitals as First California Site for ARYA-2 Clinical Trial Targeting Pediatric Liver Cancers
Press releases
18 March 2024
Eureka Therapeutics Advances ARYA-3 Clinical Trial to Phase II for Treatment of Liver Cancer Using GPC3-Targeting ARTEMIS® T-cell Therapy
2023
06 June 2023
Eureka Therapeutics Awarded $10.6 Million CIRM Grant to Support Clinical Trial of ARTEMIS® T-Cell Therapy in Pediatric Liver Cancer
Press releases
14 March 2023
Eureka Therapeutics Licenses Promising Antibody Targeting Mesothelin from the National Cancer Institute
Press releases
18 October 2022
Eureka Therapeutics Announces License with the National Cancer Institute to Advance GPC2 ARTEMIS® T Cell Therapy for Neuroblastoma
Press releases
17 October 2022
Eureka Therapeutics Receives Orphan Drug Designations for Treatment of Hepatoblastoma with ET140203 ARTEMIS® T cells
2022
28 September 2022
Eureka Therapeutics Announces New England Journal of Medicine Publication of Clinical Study Demonstrating GPRC5D as an Active Target for the Treatment of Multiple Myeloma
Press releases
03 August 2022
Eureka Therapeutics Announces Publication of Crystal Structure of TCR Mimic Redirected T Cells Targeting Alpha-Fetoprotein (AFP) for Liver Cancer
2022
06 June 2022
Eureka Therapeutics Announces Publication of Study Demonstrating Broad Anti-Tumor Activity of TCR Mimic-Redirected T Cells Targeting NDC80
2022
31 May 2022
Eureka Therapeutics and City of Hope Treat First Patient with GPC3 Targeting ARTEMIS® T Cells (ECT204) for Advanced Liver Cancer
Press releases
25 April 2022
Eureka Therapeutics to Present at the 18th Annual PEGS Boston Conference and Expo
2022
08 February 2022
Eureka Therapeutics Receives Orphan Drug Designations for Treatment of Hepatocellular Carcinoma (HCC) with ARTEMIS® T cells
MORE EUREKA NEWS

CAREERS

At Eureka, we believe that the highest performing teams include people from a wide variety of backgrounds and experiences.

JOIN OUR TEAM

Alexa Willson

CFO

Alexa Willson has served as the Chief Financial Officer of Eureka Therapeutics since August 2022. Prior to joining the company, She was a Managing Partner of Cloudstone Venture Capital, an early-stage healthtech venture firm since October 2020. Cloudstone is also an investor of Eureka Therapeutics.

Ms. Willson has over 25 years of experience advising public and private companies on corporate finance, strategy, capital raising, valuation, mergers & acquisitions, and other matters. She has founded and run a midmarket investment banking boutique and worked with large Wall Street investment banks, including Kidder Peabody and Drexel Burnham.

Ms. Willson has served on private and non-profit boards and investment committees in various capacities. She teaches financial literacy. Ms. Willson holds a BA from Harvard and an MBA from Stanford Graduate School of Business.